Radical shifts in the first-line management of metastatic renal cell carcinoma

Radical shifts in the first-line management of metastatic renal cell carcinomaRadical shifts in the first-line management of metastatic renal cell carcinoma, Published online: 11 December 2018; doi:10.1038/s41571-018-0146-4In 2018, the results of multiple phase III trials in metastatic renal cell carcinoma (mRCC) were presented. A phase III noninferiority trial demonstrated the importance of careful patient selection before cytoreductive nephrectomy. Additionally, three randomized phase III trials demonstrated the superiority of combination therapy with an immune-checkpoint inhibitor backbone versus sunitinib in patients with treatment-naive mRCC.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research